Dovato 50 mg/300 mg film-coated tablets clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed
This study is looking at an HIV medication called Dovato. It's for people aged 50 or older who are already stable on another HIV medicine, Biktarvy. Researchers want to see if switching to Dovato is safe, works well, and is easy to take.
For: Human immunodeficiency virus (HIV)Belgium · Italy · Portugal - Ongoing, recruitingTherapeutic use (Phase IV)
Phase IV, Randomized, Multicenter, Double-Blind Clinical Trial Designed to Evaluate the Safety and Appropriateness of Switching from DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control, and Neuropsychiatric Vulnerabilities: MIND Study
This study is looking at how switching HIV medication might affect your mood, thinking, and sleep. It's for people with HIV who are doing well on their current treatment but might have some brain-related symptoms. Researchers want to see if switching to Biktarvy is safe and helpful.
For: HIVSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase IIIb, multi-center, non-randomized, parallel-group, open-label, hybrid type I study evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral dolutegravir/lamivudine once-daily as a first-line regimen followed by participant-determined optional switch to long-acting intramuscular cabotegravir plus rilpivirine every two months for the maintenance of virologic suppression in antiretroviral therapy naive adults living with HIV-1.
This study looks at new ways to treat HIV-1 in adults who haven't had treatment before. It starts with daily tablets, and then some people can switch to injections every two months. The aim is to see how well these treatments work, if they're safe, and how they affect patients' lives.
For: HIV-1 infectionItaly · France · Spain - Ongoing, recruitingPhase III and phase IV (Integrated)
DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial
This study compares two common HIV treatments, Biktarvy and Dovato, to see if they are equally good at keeping the virus under control. Researchers want to find out if Dovato is as effective as Biktarvy in maintaining a very low amount of HIV in the blood.
For: HIVSpain - Ongoing, recruitingTherapeutic use (Phase IV)
Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.
This study looks at how well two different HIV treatments, Biktarvy and Dovato, work in people living with HIV. It compares a 2-drug treatment to a 3-drug treatment to see which is more effective at controlling the virus and keeping the immune system healthy.
For: human immunodeficiency viruses (HIV)Belgium